CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RPS20 (ImmuneEditome ID:6224)

1. Gene summary of enriched editing regions for RPS20

check button Gene summary
Gene informationGene symbol

RPS20

Gene ID

6224

GeneSynonymsS20|uS10
GeneCytomap

8q12.1

GeneTypeprotein-coding
GeneDescription40S ribosomal protein S20|small ribosomal subunit protein uS10
GeneModificationdate20230329
UniprotIDE5RJX2;P60866;G3XAN0;E5RIP1;A0A7P0S5H5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr8:56067393-56070677:-ENST00000519807.4ENSG00000008988.8RPS20exonicAluYg6,L1MB2,AluY,MIR,AluSx,AluJo,AluSz6,MER2,L1ME3G,HAL1ME,L1MC5chr8:56067393-56070677:-.alignment
chr8:56067393-56070677:-ENST00000618656.1ENSG00000008988.8RPS20exonicAluYg6,L1MB2,AluY,MIR,AluSx,AluJo,AluSz6,MER2,L1ME3G,HAL1ME,L1MC5chr8:56067393-56070677:-.alignment
chr8:56072080-56072501:-ENST00000519807.4ENSG00000008988.8RPS20intronicAluSx1,AluJochr8:56072080-56072501:-.alignment
chr8:56072080-56072501:-ENST00000618656.1ENSG00000008988.8RPS20intronicAluSx1,AluJochr8:56072080-56072501:-.alignment


Top

2. Tumor-specific enriched editing regions for RPS20


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr8:56067393-56070677:-BRCAEER2.3264e-05image
ENSG00000008988.8,RPS20BRCAEAG2.9937e-05image
chr8:56067393-56070677:-KIRCEER1.9618e-07image
ENSG00000008988.8,RPS20KIRCEAG1.6082e-07image
chr8:56067393-56070677:-KIRPEER3.1069e-03image
ENSG00000008988.8,RPS20KIRPEAG2.8476e-03image
chr8:56067393-56070677:-UCECEER7.9442e-03image
ENSG00000008988.8,RPS20UCECEAG7.3490e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000008988.8,RPS20READPathEAG1.4520e-021.9147e-02-0.3042image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr8:56067393-56070677:-OVEER3.6001e-021.6605e-031.9020e+01image
ENSG00000008988.8,RPS20OVEAG1.6575e-021.3640e-031.9646e+01image

Top

3. Enriched editing regions and immune related genes for RPS20


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:56067393-56070677:-KIRPEERENSG00000138031,ADCY30.26874.5293e-041.4971e-100.4006imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_CD8GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr8:56067393-56070677:-ESCAEERENSG00000267904,CTC-429P9.5-0.41832.8374e-043.9193e-07-0.4014imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr8:56067393-56070677:-ESCAEERENSG00000167378,IRGQ-0.40256.4912e-042.3516e-07-0.4083imageNEIF4A3;FUS;IGF2BP2;TARDBPIRGQT_cells_CD4_memory_restingGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr8:56067393-56070677:-ESCAEERENSG00000262454,RP11-65J21.30.30461.4900e-021.7786e-070.4120imageNEIF4A3;FUS;IGF2BP2;TARDBPNAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
chr8:56067393-56070677:-ESCAEERENSG00000175592,FOSL10.29232.3322e-022.2511e-070.4089imageNEIF4A3;FUS;IGF2BP2;TARDBPFOSL1T_cells_regulatory_(Tregs)GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr8:56067393-56070677:-ESCAEERENSG00000006327,TNFRSF12A0.28073.6772e-024.6265e-080.4294imageNEIF4A3;IGF2BP2;TARDBPTNFRSF12AT_cells_regulatory_(Tregs)GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr8:56067393-56070677:-UVMEERENSG00000108175,ZMIZ1-0.45303.4808e-031.6404e-04-0.4192imageNEIF4A3;FUS;IGF2BP2;TARDBPNANK_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr8:56067393-56070677:-UVMEERENSG00000145685,LHFPL2-0.44313.5234e-032.1869e-04-0.4119imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr8:56067393-56070677:-UVMEERENSG00000120451,SNX19-0.45234.0786e-032.7670e-04-0.4057imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr8:56067393-56070677:-UVMEERENSG00000156990,RPUSD30.39737.9185e-037.9447e-050.4369imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_CD8GSVA_HALLMARK_NOTCH_SIGNALING
chr8:56067393-56070677:-KIRPEERENSG00000138031,ADCY30.26874.5293e-041.4971e-100.4006imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_CD8GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING
chr8:56067393-56070677:-ESCAEERENSG00000267904,CTC-429P9.5-0.41832.8374e-043.9193e-07-0.4014imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
chr8:56067393-56070677:-ESCAEERENSG00000167378,IRGQ-0.40256.4912e-042.3516e-07-0.4083imageNEIF4A3;FUS;IGF2BP2;TARDBPIRGQT_cells_CD4_memory_restingGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr8:56067393-56070677:-ESCAEERENSG00000262454,RP11-65J21.30.30461.4900e-021.7786e-070.4120imageNEIF4A3;FUS;IGF2BP2;TARDBPNAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
chr8:56067393-56070677:-ESCAEERENSG00000175592,FOSL10.29232.3322e-022.2511e-070.4089imageNEIF4A3;FUS;IGF2BP2;TARDBPFOSL1T_cells_regulatory_(Tregs)GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr8:56067393-56070677:-ESCAEERENSG00000006327,TNFRSF12A0.28073.6772e-024.6265e-080.4294imageNEIF4A3;IGF2BP2;TARDBPTNFRSF12AT_cells_regulatory_(Tregs)GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr8:56067393-56070677:-UVMEERENSG00000108175,ZMIZ1-0.45303.4808e-031.6404e-04-0.4192imageNEIF4A3;FUS;IGF2BP2;TARDBPNANK_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr8:56067393-56070677:-UVMEERENSG00000145685,LHFPL2-0.44313.5234e-032.1869e-04-0.4119imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr8:56067393-56070677:-UVMEERENSG00000120451,SNX19-0.45234.0786e-032.7670e-04-0.4057imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr8:56067393-56070677:-UVMEERENSG00000156990,RPUSD30.39737.9185e-037.9447e-050.4369imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_CD8GSVA_HALLMARK_NOTCH_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for RPS20


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:56067393-56070677:-
ESCAEERIRENSG00000143110.7chr1111476797:111477428:111477725:111477775-0.34199.3685e-032.1238e-06-0.4094imageNFUS;IGF2BP2NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
ENSG00000008988.8,RPS20
ESCAEAGIRENSG00000143110.7chr1111476797:111477428:111477725:111477775-0.33911.2265e-023.0033e-06-0.4039imageNCPSF6;CSTF2T;DDX42;DKC1;ELAVL1;FBL;FUS;GTF2F1;HNRNPA1;HNRNPK;HNRNPL;HNRNPU;IGF2BP1;IGF2BP2;KHDRBS1;KHSRP;LSM11;NOP56;NOP58;PRPF8;RBFOX2;RBM10;SAFB2;SF3B4;SRSF1;U2AF2;XRN2NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr8:56067393-56070677:-
KIRPEERESENSG00000142676.8chr123693810:23693913:23694679:23694791:23695797:236959080.05091.7028e-022.6648e-100.4454imageNEIF4A3;FUS;IGF2BP2;TARDBPRPL11T_cells_CD8GSVA_HALLMARK_MYC_TARGETS_V2
ENSG00000008988.8,RPS20
KIRPEAGESENSG00000142676.8chr123693810:23693913:23694679:23694791:23695797:236959080.05101.7623e-022.0872e-100.4477imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184RPL11T_cells_CD8GSVA_HALLMARK_MYC_TARGETS_V2
chr8:56067393-56070677:-
THYMEERESENSG00000165501.12chr1449602369:49602468:49607399:49608121:49614255:496146700.43332.8371e-042.2056e-060.4594imageNEIF4A3;FUS;IGF2BP2;TARDBPLRR1T_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000008988.8,RPS20
THYMEAGIRENSG00000115317.7chr274529724:74529912:74530460:745305120.40732.9202e-033.5818e-060.4273imageNADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184HTRA2T_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
ENSG00000008988.8,RPS20
THYMEAGIRENSG00000127774.6chr173668821:3669012:3669097:3669665-0.34941.8934e-022.5839e-06-0.4366imageNAIFM1;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPC;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHDRBS3;LARP4B;LIN28;LIN28A;LIN28B;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RTCB;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAMacrophages_M1GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:56067393-56070677:-
THYMEERIRENSG00000008853.12chr823004043:23006145:23006727:23007746-0.38197.1516e-045.7714e-06-0.4508imageNEIF4A3;FUS;IGF2BP2;TARDBPNAMacrophages_M1GSVA_HALLMARK_PROTEIN_SECRETION
chr8:56067393-56070677:-
THYMEERMEXENSG00000160310.12chr2146649697:46649739:46658744:46658920:46661799:46661936:46663382:466635540.43051.1452e-039.3221e-060.4052imageNEIF4A3;FUS;IGF2BP2;TARDBPNAMacrophages_M1GSVA_HALLMARK_PROTEIN_SECRETION
chr8:56067393-56070677:-
THYMEERIRENSG00000162910.14chr1228107667:228108318:228109260:2281092900.38201.0846e-029.1490e-070.4409imageNEIF4A3;FUS;IGF2BP2;TARDBPNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR

More results



Top

5. Enriched editing regions and immune infiltration for RPS20


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr8:56067393-56070677:-ACCEERDendritic_cells_activated9.8152e-040.4216image
ENSG00000008988.8,RPS20ACCEAGDendritic_cells_activated9.8152e-040.4216image
chr8:56067393-56070677:-BLCAEERT_cells_regulatory_(Tregs)8.6141e-03-0.2009image
ENSG00000008988.8,RPS20BLCAEAGT_cells_regulatory_(Tregs)8.6141e-03-0.2009image
chr8:56067393-56070677:-BRCAEERMacrophages_M23.3084e-02-0.0741image
ENSG00000008988.8,RPS20BRCAEAGMacrophages_M23.9339e-02-0.0716image
chr8:56067393-56070677:-CESCEERMonocytes4.6421e-060.3712image
ENSG00000008988.8,RPS20CESCEAGMonocytes4.6421e-060.3712image
chr8:56067393-56070677:-CHOLEERNK_cells_resting4.3868e-020.3908image
ENSG00000008988.8,RPS20CHOLEAGNK_cells_resting4.3868e-020.3908image
chr8:56067393-56070677:-COADEERDendritic_cells_activated1.0069e-030.2779image
ENSG00000008988.8,RPS20COADEAGDendritic_cells_activated1.0069e-030.2779image
chr8:56067393-56070677:-ESCAEERT_cells_regulatory_(Tregs)1.3026e-04-0.3084image
chr8:56072080-56072501:-ESCAEERT_cells_CD4_memory_activated1.9021e-030.3753image
ENSG00000008988.8,RPS20ESCAEAGT_cells_regulatory_(Tregs)6.6764e-05-0.3207image
chr8:56067393-56070677:-GBMEERT_cells_CD4_memory_resting1.8596e-030.2420image
chr8:56072080-56072501:-GBMEERT_cells_CD4_memory_activated4.9921e-020.2682image
ENSG00000008988.8,RPS20GBMEAGT_cells_CD4_memory_resting1.5254e-030.2463image
chr8:56067393-56070677:-KICHEERNeutrophils1.8056e-020.3817image
ENSG00000008988.8,RPS20KICHEAGNeutrophils1.7818e-020.3824image
chr8:56067393-56070677:-KIRCEERMacrophages_M14.6215e-020.1085image
ENSG00000008988.8,RPS20KIRCEAGMacrophages_M14.5876e-020.1085image
chr8:56067393-56070677:-KIRPEERMast_cells_resting1.0846e-02-0.1652image
ENSG00000008988.8,RPS20KIRPEAGMast_cells_resting1.7114e-02-0.1548image
chr8:56067393-56070677:-LGGEERT_cells_CD4_memory_activated5.5684e-060.1960image
ENSG00000008988.8,RPS20LGGEAGT_cells_CD4_memory_activated3.4314e-060.2003image
chr8:56067393-56070677:-LIHCEERMacrophages_M03.9971e-02-0.1720image
ENSG00000008988.8,RPS20LIHCEAGMacrophages_M03.9971e-02-0.1720image
chr8:56067393-56070677:-LUADEERNeutrophils2.3949e-020.2061image
ENSG00000008988.8,RPS20LUADEAGNeutrophils2.2130e-020.2079image
chr8:56067393-56070677:-LUSCEERT_cells_CD4_memory_activated3.8987e-020.1536image
ENSG00000008988.8,RPS20LUSCEAGT_cells_CD4_memory_activated3.9411e-020.1533image
chr8:56067393-56070677:-OVEERT_cells_CD82.0378e-030.1880image
chr8:56072080-56072501:-OVEERMacrophages_M04.6793e-02-0.2535image
ENSG00000008988.8,RPS20OVEAGT_cells_CD82.7831e-030.1824image
ENSG00000008988.8,RPS20PAADEAGT_cells_regulatory_(Tregs)1.0272e-020.2820image
chr8:56067393-56070677:-PCPGEERMast_cells_resting2.9005e-02-0.1614image
ENSG00000008988.8,RPS20PCPGEAGMast_cells_resting3.0035e-02-0.1604image
chr8:56067393-56070677:-PRADEERT_cells_CD88.1053e-03-0.1227image
ENSG00000008988.8,RPS20PRADEAGT_cells_CD88.6552e-03-0.1215image
ENSG00000008988.8,RPS20READEAGT_cells_CD4_memory_resting8.5249e-030.3718image
chr8:56067393-56070677:-SKCMEERMast_cells_resting3.3093e-02-0.1201image
ENSG00000008988.8,RPS20SKCMEAGMast_cells_resting3.4686e-02-0.1190image
chr8:56067393-56070677:-STADEERMacrophages_M27.2045e-030.1495image
chr8:56072080-56072501:-STADEEREosinophils1.7222e-040.3134image
ENSG00000008988.8,RPS20STADEAGMonocytes1.7080e-020.1326image
chr8:56067393-56070677:-THCAEERDendritic_cells_activated1.5702e-040.1708image
ENSG00000008988.8,RPS20THCAEAGDendritic_cells_activated1.6321e-040.1704image
chr8:56067393-56070677:-THYMEERMacrophages_M11.8690e-060.4294image
ENSG00000008988.8,RPS20THYMEAGMacrophages_M12.4887e-060.4247image
chr8:56067393-56070677:-UVMEERDendritic_cells_activated1.9099e-020.2683image
ENSG00000008988.8,RPS20UVMEAGDendritic_cells_activated1.9095e-020.2683image


Top

6. Enriched editing regions and immune gene sets for RPS20


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr8:56067393-56070677:-BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.3515e-080.4185image
ENSG00000008988.8,RPS20BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.3515e-080.4185image
chr8:56067393-56070677:-BRCAGSVA_HALLMARK_HEME_METABOLISMEER1.7634e-080.1942image
ENSG00000008988.8,RPS20BRCAGSVA_HALLMARK_HEME_METABOLISMEAG7.6793e-080.1853image
chr8:56067393-56070677:-CESCGSVA_HALLMARK_DNA_REPAIREER8.3076e-03-0.2192image
ENSG00000008988.8,RPS20CESCGSVA_HALLMARK_DNA_REPAIREAG8.3076e-03-0.2192image
chr8:56067393-56070677:-CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER5.1550e-030.5227image
ENSG00000008988.8,RPS20CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG5.1550e-030.5227image
chr8:56067393-56070677:-ESCAGSVA_HALLMARK_HYPOXIAEER1.6489e-050.3449image
chr8:56072080-56072501:-ESCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.3925e-020.2778image
ENSG00000008988.8,RPS20ESCAGSVA_HALLMARK_HYPOXIAEAG1.4545e-050.3470image
chr8:56067393-56070677:-GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.7785e-060.3531image
chr8:56072080-56072501:-GBMGSVA_HALLMARK_P53_PATHWAYEER1.8022e-040.4882image
ENSG00000008988.8,RPS20GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.9894e-060.3566image
chr8:56067393-56070677:-HNSCGSVA_HALLMARK_E2F_TARGETSEER1.0515e-03-0.2359image
ENSG00000008988.8,RPS20HNSCGSVA_HALLMARK_E2F_TARGETSEAG9.5833e-04-0.2377image
chr8:56067393-56070677:-KICHGSVA_HALLMARK_HEME_METABOLISMEER2.4122e-030.4779image
ENSG00000008988.8,RPS20KICHGSVA_HALLMARK_HEME_METABOLISMEAG2.4891e-030.4766image
ENSG00000008988.8,RPS20KIRCGSVA_HALLMARK_MYOGENESISEAG6.5914e-03-0.1473image
chr8:56067393-56070677:-KIRCGSVA_HALLMARK_MYOGENESISEER6.4255e-03-0.1480image
ENSG00000008988.8,RPS20KIRPGSVA_HALLMARK_MTORC1_SIGNALINGEAG3.5191e-030.1889image
chr8:56067393-56070677:-KIRPGSVA_HALLMARK_MTORC1_SIGNALINGEER3.5726e-030.1886image
ENSG00000008988.8,RPS20LGGGSVA_HALLMARK_ANGIOGENESISEAG2.3359e-050.1828image
chr8:56067393-56070677:-LGGGSVA_HALLMARK_ANGIOGENESISEER8.4535e-050.1701image
chr8:56067393-56070677:-LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.4404e-030.2268image
ENSG00000008988.8,RPS20LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG6.4404e-030.2268image
chr8:56067393-56070677:-LUADGSVA_HALLMARK_HEME_METABOLISMEER2.1319e-020.2100image
ENSG00000008988.8,RPS20LUADGSVA_HALLMARK_COAGULATIONEAG2.6175e-020.2022image
chr8:56067393-56070677:-LUSCGSVA_HALLMARK_MYC_TARGETS_V1EER3.2131e-030.2179image
ENSG00000008988.8,RPS20LUSCGSVA_HALLMARK_MYC_TARGETS_V1EAG3.0648e-030.2189image
ENSG00000008988.8,RPS20MESOGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5116e-020.3098image
chr8:56067393-56070677:-MESOGSVA_HALLMARK_PROTEIN_SECRETIONEER1.5414e-020.3089image
chr8:56072080-56072501:-OVGSVA_HALLMARK_UV_RESPONSE_UPEER4.2158e-050.4956image
ENSG00000008988.8,RPS20OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1187e-070.3111image
chr8:56067393-56070677:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.8127e-070.3022image
ENSG00000008988.8,RPS20PAADGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.9660e-030.3369image
ENSG00000008988.8,RPS20PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.6678e-050.2881image
chr8:56067393-56070677:-PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.3966e-050.2866image
ENSG00000008988.8,RPS20PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.5664e-070.2400image
chr8:56067393-56070677:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER1.3044e-070.2418image
ENSG00000008988.8,RPS20READGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG7.1912e-030.3793image
ENSG00000008988.8,RPS20SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.1013e-050.2693image
chr8:56067393-56070677:-SARCGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.6189e-050.2711image
chr8:56067393-56070677:-SKCMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER8.2094e-040.1876image
ENSG00000008988.8,RPS20SKCMGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG8.4095e-040.1872image
ENSG00000008988.8,RPS20STADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.1724e-080.3107image
chr8:56072080-56072501:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.9169e-020.1752image
chr8:56067393-56070677:-STADGSVA_HALLMARK_APOPTOSISEER7.9982e-090.3145image
chr8:56067393-56070677:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1800e-020.3016image
ENSG00000008988.8,RPS20TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1800e-020.3016image
ENSG00000008988.8,RPS20THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG4.1933e-050.1849image
chr8:56067393-56070677:-THCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER3.8343e-050.1858image
ENSG00000008988.8,RPS20THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG8.3806e-060.4038image
chr8:56067393-56070677:-THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER7.5423e-060.4057image
ENSG00000008988.8,RPS20UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.6116e-030.2356image
chr8:56067393-56070677:-UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6797e-030.2352image
chr8:56067393-56070677:-UCSGSVA_HALLMARK_APOPTOSISEER4.4211e-030.3922image
ENSG00000008988.8,RPS20UCSGSVA_HALLMARK_APOPTOSISEAG4.4161e-030.3922image
ENSG00000008988.8,RPS20UVMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.9514e-03-0.3269image
chr8:56067393-56070677:-UVMGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.9987e-03-0.3265image


Top

7. Enriched editing regions and drugs for RPS20


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000008988.8,RPS20ACCAS601245EAG4.5080e-040.4460image
chr8:56067393-56070677:-ACCAS601245EER4.5080e-040.4460image
ENSG00000008988.8,RPS20BLCACGP.082996EAG2.1819e-04-0.2799image
chr8:56067393-56070677:-BLCACGP.082996EER2.1819e-04-0.2799image
ENSG00000008988.8,RPS20BRCAABT.263EAG5.6786e-040.1197image
chr8:56067393-56070677:-BRCAABT.263EER4.2021e-040.1225image
chr8:56067393-56070677:-CESCAZ628EER4.4502e-030.2374image
ENSG00000008988.8,RPS20CESCAZ628EAG4.4502e-030.2374image
chr8:56067393-56070677:-CHOLEHT.1864EER4.9554e-030.5247image
ENSG00000008988.8,RPS20CHOLEHT.1864EAG4.9554e-030.5247image
ENSG00000008988.8,RPS20COADBI.2536EAG1.7309e-040.3155image
chr8:56067393-56070677:-COADBI.2536EER1.7309e-040.3155image
chr8:56072080-56072501:-ESCAAZD.0530EER2.6892e-02-0.2724image
ENSG00000008988.8,RPS20ESCACGP.60474EAG2.6732e-06-0.3737image
chr8:56067393-56070677:-ESCACGP.60474EER4.2030e-06-0.3668image
ENSG00000008988.8,RPS20GBMBIBW2992EAG3.3400e-07-0.3870image
chr8:56072080-56072501:-GBMCI.1040EER2.9938e-03-0.3965image
chr8:56067393-56070677:-GBMBIBW2992EER3.7498e-07-0.3855image
chr8:56067393-56070677:-HNSCLFM.A13EER3.8888e-04-0.2548image
ENSG00000008988.8,RPS20HNSCLFM.A13EAG3.7271e-04-0.2556image
chr8:56067393-56070677:-KICHEmbelinEER9.8805e-04-0.5131image
ENSG00000008988.8,RPS20KICHEmbelinEAG1.1018e-03-0.5090image
ENSG00000008988.8,RPS20KIRCABT.888EAG4.4809e-04-0.1899image
chr8:56067393-56070677:-KIRCABT.888EER2.5687e-04-0.1979image
chr8:56067393-56070677:-KIRPJNK.9LEER5.7012e-06-0.2899image
ENSG00000008988.8,RPS20KIRPJNK.9LEAG5.4595e-06-0.2905image
ENSG00000008988.8,RPS20LAMLCGP.60474EAG4.7196e-02-0.2617image
chr8:56067393-56070677:-LAMLCGP.60474EER4.8040e-02-0.2608image
ENSG00000008988.8,RPS20LGGBI.2536EAG1.4556e-170.3593image
chr8:56067393-56070677:-LGGBI.2536EER3.1670e-170.3557image
chr8:56067393-56070677:-LIHCGSK.650394EER1.0933e-040.3179image
ENSG00000008988.8,RPS20LIHCGSK.650394EAG1.0933e-040.3179image
chr8:56067393-56070677:-LUADABT.888EER9.7523e-030.2351image
ENSG00000008988.8,RPS20LUADABT.888EAG8.2623e-030.2391image
chr8:56067393-56070677:-LUSCLFM.A13EER1.1838e-020.1867image
ENSG00000008988.8,RPS20LUSCLFM.A13EAG1.1479e-020.1875image
chr8:56067393-56070677:-MESOCyclopamineEER4.6494e-040.4346image
ENSG00000008988.8,RPS20MESOCyclopamineEAG5.0727e-040.4320image
chr8:56072080-56072501:-OVMG.132EER1.3228e-04-0.4666image
chr8:56067393-56070677:-OVCCT007093EER2.4010e-040.2230image
ENSG00000008988.8,RPS20OVAG.014699EAG2.9742e-040.2197image
ENSG00000008988.8,RPS20PAADAxitinibEAG2.5417e-020.2483image
chr8:56067393-56070677:-PCPGGW843682XEER8.5653e-070.3544image
ENSG00000008988.8,RPS20PCPGGW843682XEAG1.0445e-060.3518image
chr8:56067393-56070677:-PRADCEP.701EER2.6998e-100.2874image
ENSG00000008988.8,RPS20PRADCEP.701EAG3.1925e-100.2860image
ENSG00000008988.8,RPS20READAZ628EAG4.0763e-020.2934image
chr8:56067393-56070677:-SARCGSK.650394EER6.6385e-040.2248image
ENSG00000008988.8,RPS20SARCGSK.650394EAG6.2203e-040.2259image
ENSG00000008988.8,RPS20SKCMCytarabineEAG5.3343e-030.1566image
chr8:56067393-56070677:-SKCMCytarabineEER5.6901e-030.1555image
ENSG00000008988.8,RPS20STADCI.1040EAG4.1567e-04-0.1953image
chr8:56067393-56070677:-STADAZ628EER5.1486e-04-0.1925image
chr8:56072080-56072501:-STADBleomycinEER1.7546e-030.2631image
ENSG00000008988.8,RPS20TGCTBMS.708163EAG2.1370e-03-0.3636image
chr8:56067393-56070677:-TGCTBMS.708163EER2.1370e-03-0.3636image
chr8:56067393-56070677:-THCACytarabineEER2.5048e-100.2822image
ENSG00000008988.8,RPS20THCACytarabineEAG2.9892e-100.2810image
chr8:56067393-56070677:-THYMAZD8055EER8.6909e-090.5069image
ENSG00000008988.8,RPS20THYMAZD8055EAG1.1106e-080.5037image
ENSG00000008988.8,RPS20UCECEHT.1864EAG5.8207e-030.2295image
chr8:56067393-56070677:-UCECEHT.1864EER5.9049e-030.2292image
ENSG00000008988.8,RPS20UCSKIN001.135EAG2.3916e-03-0.4161image
chr8:56067393-56070677:-UCSKIN001.135EER2.3181e-03-0.4172image
chr8:56067393-56070677:-UVMBicalutamideEER1.8739e-02-0.2691image
ENSG00000008988.8,RPS20UVMBicalutamideEAG1.8627e-02-0.2694image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType